A Study of MK0431 in Patients With Type 2 Diabetes - Full Text View

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00482079

Purpose

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

Condition	Intervention	Phase
Diabetes Mellitus, Type II	Drug: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks Drug: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks	Phase II

MedlinePlus related topics: Diabetes

Drug Information available for: Sitagliptin phosphate Sitagliptin

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Further study details as provided by Merck:

Primary Outcome Measures:

To asses the effectiveness of MK0431 compared to placebo [ Time Frame: over 12 weeks ]

Secondary Outcome Measures:

Estimated Enrollment:	600
Study Start Date:	July 2004

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Have a history of type I diabetes
You are on a weight loss program with ongoing weight loss or taking weight loss medications
You have a history of minor surgery
You have received investigational drugs within 8 weeks of study start
You have hepatitis B or C

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00482079

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Publications:

Study ID Numbers:	2007_578
Study First Received:	June 1, 2007
Last Updated:	October 8, 2007
ClinicalTrials.gov Identifier:	NCT00482079
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Signs and Symptoms
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases

Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Sitagliptin

Additional relevant MeSH terms:

Dipeptidyl-Peptidase IV Inhibitors
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Pharmacologic Actions
Protease Inhibitors

ClinicalTrials.gov processed this record on January 14, 2009